PMID- 32468023
OWN - NLM
STAT- MEDLINE
DCOM- 20210505
LR  - 20210914
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 57
IP  - 2
DP  - 2020 Aug
TI  - Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer 
      immunotherapy in a murine lung cancer model.
PG  - 587-597
LID - 10.3892/ijo.2020.5073 [doi]
AB  - While dendritic cell (DC)‑based immunotherapy has achieved satisfactory results 
      in animal models, its effects were not satisfactory as initially expected in 
      clinical applications, despite the safety and varying degrees of effectiveness in 
      various types of cancer. Improving the efficacy of the DC‑based vaccine is 
      essential for cancer immunotherapy. The present study aimed to investigate 
      methods with which to amplify and enhance the antitumor immune response of a 
      DC‑based tumor vaccine by silencing the expression of indoleamine 2,3‑dioxygenase 
      2 (IDO2), a tryptophan rate‑limiting metabolic enzyme in DCs. In vitro 
      experiments revealed that the silencing of IDO2 in DCs did not affect the 
      differentiation of DCs, whereas it increased their expression of costimulatory 
      molecules following stimulation with tumor necrosis factor (TNF)‑alpha and tumor 
      lysate from Lewis lung cancer (LLC) cells. In a mixed co‑culture system, the 
      IDO2‑silenced DCs promoted the proliferation of T‑cells and reduced the induction 
      of regulatory T‑cells (Tregs). Further in vivo experiments revealed that the 
      silencing of IDO2 in DCs markedly suppressed the growth of tumor cells. Moreover, 
      treatment with the IDO2‑silenced DC‑based cancer vaccine enhanced cytotoxic T 
      lymphocyte activity, whereas it decreased T‑cell apoptosis and the percentage of 
      CD4+CD25+Foxp3+ Tregs. On the whole, the present study provides evidence that the 
      silencing of the tryptophan rate‑limiting metabolic enzyme, IDO2, has the 
      potential to enhance the efficacy of DC‑based cancer immunotherapy.
FAU - Liu, Yanling
AU  - Liu Y
AD  - Medical Laboratory, Jiangxi University of Technology, Nanchang, Jiangxi 330098, 
      P.R. China.
FAU - Xu, Ping
AU  - Xu P
AD  - Medical Laboratory, Jiangxi University of Technology, Nanchang, Jiangxi 330098, 
      P.R. China.
FAU - Liu, Huan
AU  - Liu H
AD  - Medical Laboratory, Jiangxi University of Technology, Nanchang, Jiangxi 330098, 
      P.R. China.
FAU - Fang, Chunjuan
AU  - Fang C
AD  - Medical Laboratory, Jiangxi University of Technology, Nanchang, Jiangxi 330098, 
      P.R. China.
FAU - Guo, Haihe
AU  - Guo H
AD  - Medical Laboratory, Jiangxi University of Technology, Nanchang, Jiangxi 330098, 
      P.R. China.
FAU - Chen, Xiaoyan
AU  - Chen X
AD  - Medical Laboratory, Jiangxi University of Technology, Nanchang, Jiangxi 330098, 
      P.R. China.
FAU - Tan, Manman
AU  - Tan M
AD  - Institute of Immunotherapy, Nanchang University and Jiangxi Academy of Medical 
      Science, Nanchang, Jiangxi 330098, P.R. China.
FAU - Zhang, Yujuan
AU  - Zhang Y
AD  - Institute of Immunotherapy, Nanchang University and Jiangxi Academy of Medical 
      Science, Nanchang, Jiangxi 330098, P.R. China.
FAU - Min, Weiping
AU  - Min W
AD  - Institute of Immunotherapy, Nanchang University and Jiangxi Academy of Medical 
      Science, Nanchang, Jiangxi 330098, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Cancer Vaccines)
RN  - 0 (IDO2 protein, mouse)
RN  - 0 (Indoleamine-Pyrrole 2,3,-Dioxygenase)
RN  - 0 (Tnf protein, mouse)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 8DUH1N11BX (Tryptophan)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/administration & dosage/*immunology
MH  - Carcinoma, Lewis Lung/genetics/immunology/pathology/*therapy
MH  - Cell Line, Tumor
MH  - Coculture Techniques
MH  - Dendritic Cells/*immunology/metabolism
MH  - Female
MH  - Immunotherapy/*methods
MH  - Indoleamine-Pyrrole 2,3,-Dioxygenase/*genetics/metabolism
MH  - Mice
MH  - RNA Interference
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - T-Lymphocytes, Regulatory/immunology
MH  - Tryptophan/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - dendritic cells
OT  - siRNA
OT  - IDO2
OT  - immunotherapy
OT  - lung cancer
EDAT- 2020/05/30 06:00
MHDA- 2021/05/06 06:00
CRDT- 2020/05/30 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/05/06 00:00 [accepted]
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/05/06 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.3892/ijo.2020.5073 [doi]
PST - ppublish
SO  - Int J Oncol. 2020 Aug;57(2):587-597. doi: 10.3892/ijo.2020.5073. Epub 2020 May 
      26.